Recent studies support the hypothesis that aortic stenosis (AS) develops due to
atherosclerosis affecting the aortic valve endothelium. The study's aim was to assess
Rosuvastatin on the hemodynamic progression and inflammatory markers of AS by treating
low-density lipoprotein (LDL) in patients with AS according to the National Cholesterol
Education Program Adult Treatment Panel III (NCEP-ATPIII) guidelines for one year.